Medy-Tox Inc. announces an Equity Buyback for 30,000 shares, for KRW 9,894 million.
January 10, 2020 at 05:30 am
Share
Medy-Tox Inc. (KOSDAQ:A086900) announces a share repurchases program. Under the program, the company will repurchase up to 30,000 shares for KRW 9,894 million. The purpose of the buyback is to stabilize stock price and increase shareholder value. The plan will be valid up to April 10, 2020. As of January 9, 2020, the company had 397,433 shares in treasury within scope available for dividend and had 5,667 shares in treasury through other repurchase.
Medy Tox Inc is a Korea-based company engaged in the development, manufacture and marketing of biopharmaceuticals. The Companyâs main product is type A botulium toxin biopharmaceuticals which are used as remedies for blepharospasms, hemifacial spasms, eye wrinkles, hyperhidrosis diseases and infantile cerebral palsy. Its products are also used in chin plastic surgeries. The Company provides its products under the brand names of Medytoxin, Neurox, Siax, and Neuramis. In addition, the Company develops and sells medical devices such as injectors under the brand names of Neurajet, Neurafen and others. The Company also engages in technology transfer. The Company distributes its products in domestic and overseas markets such as Japan, China, Russia and Europe.
MEDY-TOX INC. 
